On the filings, Exelixis (EXEL) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it BUY.
Cash-rich, newly-profitable biopharma trading at a cheap 18x — but the low multiple is the market pricing JAKAFI's 2028 patent cliff.
Profitable oncology compounder: 33.7% net margin, 36.2% ROE, no debt, huge buybacks, and a near-term zanzalintinib FDA decision as the upside lever.
| Metric | INCY | EXEL |
|---|---|---|
| Fundamentals score | 89 | 87 |
| Revenue growth (YoY) | +21.2% | +7.0% |
| Net income growth (YoY) | +3845.0% | +50.1% |
| Net margin | 25.0% | 33.7% |
| Return on equity | 24.9% | 36.2% |
| ROIC (est.) | 4.8% | 29.3% |
| Liabilities / Equity | 0.35 | 0.32 |
| Piotroski F-score | 5 / 9 | 7 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 6, 2026, 9:38 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:46 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.